JP2017537926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537926A5 JP2017537926A5 JP2017529778A JP2017529778A JP2017537926A5 JP 2017537926 A5 JP2017537926 A5 JP 2017537926A5 JP 2017529778 A JP2017529778 A JP 2017529778A JP 2017529778 A JP2017529778 A JP 2017529778A JP 2017537926 A5 JP2017537926 A5 JP 2017537926A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- pharmaceutical composition
- fusion polypeptide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 206010028289 Muscle atrophy Diseases 0.000 claims description 6
- 208000020832 chronic kidney disease Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 201000000585 muscular atrophy Diseases 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000024806 Brain atrophy Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000004434 Calcinosis Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010040799 Skin atrophy Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 230000010370 hearing loss Effects 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 208000016354 hearing loss disease Diseases 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 201000005991 hyperphosphatemia Diseases 0.000 claims description 3
- 230000007813 immunodeficiency Effects 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 206010027175 memory impairment Diseases 0.000 claims description 3
- 230000020763 muscle atrophy Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 230000008085 renal dysfunction Effects 0.000 claims description 3
- 208000001076 sarcopenia Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 8
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 8
- 230000002308 calcification Effects 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087516P | 2014-12-04 | 2014-12-04 | |
| US62/087,516 | 2014-12-04 | ||
| PCT/IB2015/059294 WO2016088059A1 (en) | 2014-12-04 | 2015-12-02 | Methods and compositions using klotho variant polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537926A JP2017537926A (ja) | 2017-12-21 |
| JP2017537926A5 true JP2017537926A5 (enExample) | 2019-01-17 |
Family
ID=55024183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529778A Pending JP2017537926A (ja) | 2014-12-04 | 2015-12-02 | Ｋｌｏｔｈｏ変種ポリペプチドを使用する方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10654909B2 (enExample) |
| EP (1) | EP3227319B1 (enExample) |
| JP (1) | JP2017537926A (enExample) |
| KR (1) | KR20170084332A (enExample) |
| CN (1) | CN107810201A (enExample) |
| AU (1) | AU2015356643B2 (enExample) |
| BR (1) | BR112017011398A2 (enExample) |
| CA (1) | CA2969307A1 (enExample) |
| EA (1) | EA201791238A1 (enExample) |
| MX (2) | MX2017007303A (enExample) |
| TW (1) | TW201628641A (enExample) |
| WO (1) | WO2016088059A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3031839B1 (fr) | 2015-01-19 | 2020-03-13 | Areva Stockage D'energie | Systeme electrique comprenant un empilement de cellules electrochimiques et procede de pilotage de ce systeme |
| US10632180B2 (en) | 2015-02-06 | 2020-04-28 | The Regents Of The University Of California | Methods and compositions for improved cognition |
| KR102820909B1 (ko) * | 2016-11-22 | 2025-06-13 | 클로토 테라퓨틱스, 아이엔씨. | 신규한 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법 |
| WO2019010314A1 (en) | 2017-07-06 | 2019-01-10 | Yale University | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ENDOCRINE FGF-RELATED DISEASES |
| EP3724230A4 (en) * | 2017-12-13 | 2022-01-19 | Yale University | Compositions and methods for treating or preventing endocrine fgf23-linked diseases |
| WO2019140250A1 (en) * | 2018-01-12 | 2019-07-18 | New York University | SOLUBLE α-KLOTH PROTEINS, PROTEIN FRAGMENTS, AND USES THEREOF |
| JP2022513093A (ja) * | 2018-11-21 | 2022-02-07 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 年齢関連横紋筋及び認知低下を低減する方法及び材料 |
| CN112695049A (zh) * | 2020-08-20 | 2021-04-23 | 山东兴瑞生物科技有限公司 | 修饰间充质干细胞的融合基因、质粒、修饰得到干细胞及制备方法 |
| CN112915193B (zh) * | 2021-03-05 | 2022-09-13 | 南方医科大学南方医院 | Kp-1在制备治疗慢性肺病的药物中的用途 |
| CN112915192B (zh) * | 2021-03-05 | 2022-10-25 | 南方医科大学南方医院 | Kp-1在制备治疗慢性肝病的药物中的用途 |
| US20240384250A1 (en) * | 2021-09-03 | 2024-11-21 | The Uab Research Foundation | Fibroblast growth factor 23 modulating compounds |
| WO2024168241A2 (en) * | 2023-02-10 | 2024-08-15 | The Trustees Of Indiana University | Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia |
| EP4434534A1 (en) | 2023-03-22 | 2024-09-25 | ADvantage Therapeutics, Inc. | Klotho mrna |
| US20250154487A1 (en) * | 2023-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Engineered alpha klotho polypeptides and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| ATE260974T1 (de) | 1990-06-15 | 2004-03-15 | Scios Inc | Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt |
| US5408038A (en) | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| US5541094A (en) | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
| CN1116870C (zh) | 1996-03-15 | 2003-08-06 | 萨默塞特药品有限公司 | 司立吉林在制备用于预防或治疗外周神经病的药物中的应用 |
| US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
| EP0945506B1 (en) | 1996-12-26 | 2007-02-28 | Kyowa Hakko Kogyo Co., Ltd. | Proteine avec une activite de suppression du vieillissement |
| US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
| US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| WO2000065366A1 (en) | 1999-04-22 | 2000-11-02 | Lipomed, Inc. | Nmr-method for determining the risk of developing type 2 diabetes |
| EP1194850A1 (en) | 1999-06-30 | 2002-04-10 | Microsoft Corporation | System and method for protecting shared system files |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US6406853B1 (en) | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
| JP2006238894A (ja) | 2000-02-15 | 2006-09-14 | Amgen Inc | 線維芽細胞成長因子−２３分子およびその使用 |
| CA2398603A1 (en) | 2000-02-15 | 2001-08-23 | Amgen, Inc. | Fibroblast growth factor-23 molecules and uses thereof |
| US20060160181A1 (en) | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| AU2001249125A1 (en) | 2000-03-08 | 2001-09-17 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| EP1303536B1 (en) | 2000-07-19 | 2010-03-17 | Advanced Research And Technology Institute, Inc. | Novel fibroblast growth factor (fgf23) and methods for use |
| EP1425289A4 (en) | 2001-01-30 | 2004-10-13 | Regeneron Pharma | NOVEL NUCLEIC ACID AND POLYPEPTIDE MOLECULES |
| US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| BR0209144A (pt) | 2001-04-26 | 2004-06-08 | Geneprot Inc | Composição associadas ao fator de crescimento de fibroblasto humano |
| EP1327443A1 (en) | 2001-12-21 | 2003-07-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| US20050004348A1 (en) | 2002-12-23 | 2005-01-06 | Miyamoto Ken-Ichi | Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| US20170233446A1 (en) | 2008-01-28 | 2017-08-17 | Novartis Ag | Methods and compositions using klotho-fgf fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009117622A2 (en) | 2008-03-19 | 2009-09-24 | Ambrx, Inc. | Modified fgf-23 polypeptides and their uses |
| JP5878757B2 (ja) | 2008-10-10 | 2016-03-08 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2015
- 2015-12-02 AU AU2015356643A patent/AU2015356643B2/en not_active Ceased
- 2015-12-02 CN CN201580075428.5A patent/CN107810201A/zh active Pending
- 2015-12-02 CA CA2969307A patent/CA2969307A1/en not_active Abandoned
- 2015-12-02 US US15/532,634 patent/US10654909B2/en active Active
- 2015-12-02 MX MX2017007303A patent/MX2017007303A/es unknown
- 2015-12-02 JP JP2017529778A patent/JP2017537926A/ja active Pending
- 2015-12-02 BR BR112017011398A patent/BR112017011398A2/pt not_active IP Right Cessation
- 2015-12-02 EP EP15816527.4A patent/EP3227319B1/en not_active Not-in-force
- 2015-12-02 KR KR1020177017910A patent/KR20170084332A/ko not_active Ceased
- 2015-12-02 WO PCT/IB2015/059294 patent/WO2016088059A1/en not_active Ceased
- 2015-12-02 EA EA201791238A patent/EA201791238A1/ru unknown
- 2015-12-03 TW TW104140597A patent/TW201628641A/zh unknown
-
2017
- 2017-06-05 MX MX2021000030A patent/MX2021000030A/es unknown
-
2020
- 2020-02-26 US US16/802,511 patent/US20200362015A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537926A5 (enExample) | ||
| JP2016190847A5 (enExample) | ||
| JP2015522576A5 (enExample) | ||
| JP2018171063A5 (enExample) | ||
| JP2015537044A5 (enExample) | ||
| JP2016512213A5 (enExample) | ||
| JP2021502378A5 (ja) | アクチビンＩＩａ型受容体変異体を含む医薬組成物 | |
| JP2012509687A5 (enExample) | ||
| JP2009213477A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| JP2018538356A5 (enExample) | ||
| JP2016501829A5 (enExample) | ||
| JP2009500298A5 (enExample) | ||
| JP2017070289A5 (enExample) | ||
| JP2018525989A5 (enExample) | ||
| JP2019518788A5 (enExample) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| ME02652B (me) | Stabilizovana varijanta aktivin iib receptora | |
| JP2014510519A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| JP2014508510A5 (enExample) | ||
| JP2014525901A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2025114622A (ja) | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |